Proportion of follow-up visits with laboratory tests available at which elevated liver enzyme tests* were identified, by disease and drug exposure
| RA patients (n = 1953) | PsA patients (n = 151) | |||
| Proportion with AST or ALT >1× ULN (%) | Proportion with AST or ALT >2× ULN (%) | Proportion with AST or ALT >1× ULN (%) | Proportion with AST or ALT >2× ULN (%) | |
| MTX alone | 22 | 1 | 35 | 0 |
| LEF alone | 17 | 2 | – | – |
| MTX+LEF | 31 | 5 | – | – |
| Neither MTX nor LEF | 14 | 2 | 28 | 3 |
| p Value for column | <0.01 | <0.01 | NS | NS |
*Defined as AST or ALT >1×ULN or 2×ULN.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LEF, leflunomide; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ULN, upper limit of normal; NS, not significant; –, indicates fewer than 10 PsA patients were on this treatment regimen.